CJC-1295 (no DAC) vs Sermorelin
Both CJC-1295 (no DAC) and Sermorelin are used for growth-hormone and anti-aging. Here's how their evidence, dosing, and regulatory status actually compare.
CJC-1295 (no DAC)
Evidence BModified Growth Hormone Releasing Factor 1-29
A growth hormone releasing hormone (GHRH) analog most commonly stacked with Ipamorelin to stimulate natural GH pulsatile release without disrupting the hypothalamic axis.
View full CJC-1295 (no DAC) profile →Sermorelin
Evidence B+Sermorelin Acetate (GHRH 1-29)
The original synthetic GHRH(1–29) and the most accessible GH-stimulating peptide for age-related hormone decline. Stimulates the body's own pulsatile GH release rather than replacing it.
View full Sermorelin profile →Side-by-Side
| Attribute | CJC-1295 (no DAC) | Sermorelin |
|---|---|---|
| Evidence Grade | B | B+ |
| FDA Status | Not FDA-approved — Category 1 (compounding allowed) | FDA-approved (1990) for pediatric growth hormone deficiency; off-label adult use via compounding pharmacies |
| Typical Dose | 100–300 mcg before bed (subcutaneous) | 200–500 mcg before bed (subcutaneous) |
| Clinics Indexed | 156 | 220 |
| Categories | growth-hormone, anti-aging, recovery | growth-hormone, anti-aging |
Key reported benefits — CJC-1295 (no DAC)
- ✓Growth hormone release
- ✓Fat loss
- ✓Improved sleep
- ✓Muscle recovery
Key reported benefits — Sermorelin
- ✓Natural GH release
- ✓Improved sleep
- ✓Lean body mass
- ✓Recovery
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.